Trial · NCT02675465
Participant flow72
How many started, completed or left each group, period by period.
1 to 20 of 72
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Stage 1 SAD (Cohort 1 Only) | STARTED | Cohort 1 (ERT Experienced; Ambulatory): SAD 5 to 20 mg/kg ATB200 | 11 | |
| Stage 1 SAD (Cohort 1 Only) | STARTED | Cohort 1 (ERT Experienced; Ambulatory) MAD 20 mg/kg ATB200 + 130 to 260 mg AT2221 | 0 | |
| Stage 1 SAD (Cohort 1 Only) | STARTED | Cohort 1 (ERT Experienced; Ambulatory): | 0 | |
| Stage 1 SAD (Cohort 1 Only) | STARTED | Cohort 2 (ERT Experienced; Non-ambulatory): 20 mg/kg ATB200 + 260 mg AT2221 | 0 | |
| Stage 1 SAD (Cohort 1 Only) | STARTED | Cohort 3 (ERT Naive; Ambulatory): 20 mg/kg ATB200 + 260 mg AT2221 | 0 | |
| Stage 1 SAD (Cohort 1 Only) | STARTED | Cohort 4 (ERT Experienced; Ambulatory): 20 mg/kg ATB200 + 260 mg AT2221 | 0 | |
| Stage 1 SAD (Cohort 1 Only) | COMPLETED | Cohort 1 (ERT Experienced; Ambulatory): SAD 5 to 20 mg/kg ATB200 | 11 | |
| Stage 1 SAD (Cohort 1 Only) | COMPLETED | Cohort 1 (ERT Experienced; Ambulatory) MAD 20 mg/kg ATB200 + 130 to 260 mg AT2221 | 0 | |
| Stage 1 SAD (Cohort 1 Only) | COMPLETED | Cohort 1 (ERT Experienced; Ambulatory): | 0 | |
| Stage 1 SAD (Cohort 1 Only) | COMPLETED | Cohort 2 (ERT Experienced; Non-ambulatory): 20 mg/kg ATB200 + 260 mg AT2221 | 0 | |
| Stage 1 SAD (Cohort 1 Only) | COMPLETED | Cohort 3 (ERT Naive; Ambulatory): 20 mg/kg ATB200 + 260 mg AT2221 | 0 | |
| Stage 1 SAD (Cohort 1 Only) | COMPLETED | Cohort 4 (ERT Experienced; Ambulatory): 20 mg/kg ATB200 + 260 mg AT2221 | 0 | |
| Stage 1 SAD (Cohort 1 Only) | NOT COMPLETED | Cohort 1 (ERT Experienced; Ambulatory): SAD 5 to 20 mg/kg ATB200 | 0 | |
| Stage 1 SAD (Cohort 1 Only) | NOT COMPLETED | Cohort 1 (ERT Experienced; Ambulatory) MAD 20 mg/kg ATB200 + 130 to 260 mg AT2221 | 0 | |
| Stage 1 SAD (Cohort 1 Only) | NOT COMPLETED | Cohort 1 (ERT Experienced; Ambulatory): | 0 | |
| Stage 1 SAD (Cohort 1 Only) | NOT COMPLETED | Cohort 2 (ERT Experienced; Non-ambulatory): 20 mg/kg ATB200 + 260 mg AT2221 | 0 | |
| Stage 1 SAD (Cohort 1 Only) | NOT COMPLETED | Cohort 3 (ERT Naive; Ambulatory): 20 mg/kg ATB200 + 260 mg AT2221 | 0 | |
| Stage 1 SAD (Cohort 1 Only) | NOT COMPLETED | Cohort 4 (ERT Experienced; Ambulatory): 20 mg/kg ATB200 + 260 mg AT2221 | 0 | |
| Stage 2 MAD (Cohort 1 Only) | STARTED | Cohort 1 (ERT Experienced; Ambulatory): SAD 5 to 20 mg/kg ATB200 | 0 | |
| Stage 2 MAD (Cohort 1 Only) | STARTED | Cohort 1 (ERT Experienced; Ambulatory) MAD 20 mg/kg ATB200 + 130 to 260 mg AT2221 | 11 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02675465/flow